Common Water Pill Helps Stroke Survivors Reach Blood Pressure Target, Early Trial Finds

Stroke survivors whose blood pressure stays high face a higher risk of another stroke or heart attack.
Blood pressure fell. Whether strokes do too is still an open question.
The REDUCE trial measured blood pressure, not repeat strokes, so prevention remains unproven.
Mark

What did the trial actually find?

Mimi

Adding spironolactone to usual care brought systolic pressure down to about 126, versus 133 for usual care alone, at three months.

Mark

And the goal numbers?

Mimi

52% of the drug group got under 130/80, compared with 30% of the usual-care group.

Luke

Those are blood pressure results, though. Nobody has shown fewer strokes.

Mimi

Right. Dr. Joshua said exactly that. Lower pressure is known to reduce stroke risk, but this trial didn't measure repeat strokes.

Mark

Why does that gap matter?

Luke

Because Dr. Cohen's statement that the drop may lower future strokes and heart attacks is an inference, not a finding of this study.

Mimi

The trial also ended early, at 160 people instead of 200, and about 15% lacked three-month readings.

Luke

And the drug group took slightly more blood pressure medications overall, so we can't fully isolate the spironolactone effect from that.

Mark

What should a patient take from it?

Mimi

Watch potassium, which can rise without symptoms, and dizziness. Joshua suggests bringing home readings to a clinician and asking if it fits.

  • Stroke survivors with stubbornly high blood pressure face a serious risk of another stroke or heart attack, and many have struggled to reach their targets.
  • Spironolactone, a familiar and inexpensive water pill, pulled systolic pressure down by nearly eight points and moved more patients under the 130/80 goal, 52% versus 30%.
  • The trial ended early at 160 of 200 planned participants, and about 15% lacked three-month readings, leaving the evidence thinner than the headline suggests.
  • The study proved lower pressure, not fewer repeat strokes, so larger and longer trials are now needed to answer the question that matters most.
  • Potassium levels and dizziness remain the watchpoints, and clinicians are being urged to weigh the drug case by case, with home readings in hand.

In the quiet arithmetic of recovery, a stroke survivor whose blood pressure refuses to settle has long been a difficult case for medicine. A modest and inexpensive water pill, spironolactone, has now shown in the REDUCE trial, presented at the American Heart Association's meeting in Chicago in early November 2026, that it can nudge those stubborn numbers downward. Whether that lower pressure will spare these patients a second stroke or heart attack remains a question the study was never built to answer, and the honest reading is one of promise held in open suspense.

A familiar, low-cost pill may offer new help to a group of patients who have been hard to treat: stroke survivors whose blood pressure stays high even while they take medication. The REDUCE trial, presented at the American Heart Association's Scientific Sessions in Chicago on Nov. 6 to 9, 2026, tested whether adding spironolactone, commonly called a water pill, to a survivor's existing care would push pressure lower than usual care alone.

After three months, the results favored the drug. Systolic pressure averaged about 126 in the spironolactone group and about 133 in the usual-care group, and 52% of those taking the drug reached the 130/80 goal, compared with 30% of the others. Dr. Jordana Cohen of the University of Pennsylvania, a co-lead author, described the drop as meaningful and said it may lower the risk of future strokes and heart attacks.

Outside experts urged caution about that word, "may." Dr. Alfred Joshua, an emergency physician not involved in the research, noted that controlling blood pressure is already known to reduce repeat strokes, but this study measured pressure, not the strokes themselves. Safety also matters: spironolactone can raise potassium, sometimes without symptoms, and can cause dizziness.

The researchers acknowledged limits. The trial stopped early, with 160 participants instead of 200, about 15% had no reading at three months, and the drug group was also on slightly more blood pressure medication. Larger, longer studies are needed. For now, the practical advice is to bring home readings to a clinician and ask whether this medication fits.

A cheap, long-familiar pill may help a group of patients who have been hard to treat: stroke survivors whose blood pressure stays high even on medication. That is the suggestion from the REDUCE trial, presented at the American Heart Association's Scientific Sessions, held Nov. 6-9, 2026, in Chicago.

The drug is spironolactone, commonly called a water pill. The trial asked a practical question: if you add it to what a stroke survivor is already receiving, does blood pressure come down further? Participants were split into two groups. One added spironolactone to their regular treatment. The other continued with usual post-stroke care. Researchers followed their blood pressure at home over six months.

The results at the three-month mark favored the drug. The top number, systolic pressure, averaged about 126 among people taking spironolactone and about 133 among those on usual care, a difference of nearly eight points. More of them also got under the recommended goal of 130/80: 52% of the spironolactone group, compared with 30% of the usual-care group.

Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania and a co-lead author, said in a news release that lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach their targets. In her words, adding spironolactone produced a meaningful drop that may lower the risk of future strokes and heart attacks.

That word, may, carries weight. Dr. Alfred Joshua, a California-based board-certified emergency physician and former chief medical officer who was not involved in the research, called the findings encouraging but said they do not show that the drug prevents a second stroke. He told Fox News Digital that controlling blood pressure is already known to reduce the risk of another stroke, but that this study measured blood pressure, not repeat strokes. Whether the medication leads to fewer of them, he said, remains an open question.

There are safety considerations. According to the U.S. National Library of Medicine, spironolactone helps the body shed extra salt and water, which lowers blood pressure. It also makes the body hold on to potassium, so the drug's prescribing information calls for patients to have their levels checked. Joshua said high potassium is among the main concerns because it can develop without symptoms, and the risk can be higher in people with kidney problems or those taking certain medications or potassium supplements. The drug can also lower pressure enough to cause dizziness.

The researchers acknowledged limits. The trial stopped early, with 160 participants rather than the planned 200, and about 15% had no blood pressure reading available at three months. People taking spironolactone were also on slightly more blood pressure medications overall than those receiving usual care, which complicates the comparison. The study was not designed to show whether the drug prevents another stroke or a heart attack.

The researchers say larger and longer studies are needed to answer that. In the meantime, Joshua's advice to survivors whose pressure is still high is concrete: bring your home readings to your clinician and ask whether this medication is a good fit. Fox News Digital reached out to the researchers for comment.

Whether adding spironolactone leads to fewer repeat strokes is still an open question.
— Dr. Alfred Joshua, emergency physician not involved in the study
Lowering blood pressure is the most important step in preventing another stroke.
— Dr. Jordana Cohen, University of Pennsylvania, study co-lead author
Möchten Sie die ganze Geschichte? Das Original lesen bei Fox News ↗
Kontakt FAQ